Atypical antipsychotics (AAPs) have been successfully used in early-onset schizophrenia (EOS). This review summarizes the randomized, double-blind, controlled studies of AAPs in EOS, including clozapine, risperidone, olanzapine, aripiprazole, paliperidone, quetiapine, and ziprasidone. No significant differences in efficacy between AAPs were found, with the exception of clozapine and ziprasidone. Clozapine demonstrated superior efficacy in treatment-resistant patients with EOS, whereas ziprasidone failed to demonstrate efficacy in the treatment of EOS. Our review also focuses on the onset of action and weight gain associated with AAPs. The data on onset of action of AAPs in pediatric psychiatry are scanty and inconsistent. Olanzapine appears to cause the most significant weight gain in patients with EOS, while ziprasidone and aripiprazole seem to cause the least.

Department of Child Psychiatry Charles University 2nd Faculty of Medicine and University Hospital Motol Prague Czech Republic

Zobrazit více v PubMed

Clemmensen L, Lammers Vernal D, Steinhausen HC. A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry. 2012;12:150. PubMed PMC

McClellan J, Stock S, American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI) Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2013;52:976–990. PubMed

Sadock BJ, Sadock VA, Ruiz P. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. 9th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2009.

Fleischhacker WW, Hummer M. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs. 1997;53:915–929. PubMed

Findling RL, Cavus I, Pappadopulos E, et al. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. J Child Adolesc Psychopharmacol. 2013;23:531–544. PubMed PMC

Fraguas D, Correll CU, Merchan-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol. 2011;21:621–645. PubMed

Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996;53:1090–1097. PubMed

Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006;63:721–730. PubMed

Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008;63:524–529. PubMed

Schneider C, Corrigan R, Hayes D, Kyriakopoulos M, Frangou S. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry. 2014;29:1–10. PubMed

Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004;29:133–145. PubMed

McClellan J, Sikich L, Findling RL, et al. Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry. 2007;46:969–978. PubMed

Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420–1431. PubMed

Savitz AJ, Lane R, Nuamah I, Gopal S, Hough D. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. J Am Acad Child Adolesc Psychiatry. 2015;54:126–137. PubMed

Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165:1432–1441. PubMed

Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19:611–621. PubMed

Kryzhanovskaya L, Schultz C, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:60–70. PubMed

Singh J, Robb A, Vijapurkar U, Nuamah I, Hough D. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry. 2011;70:1179–1187. PubMed

Findling RL, McKenna K, Earley WR, Stankowski J, Pathak S. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2012;22:327–342. PubMed

Thase ME. Methodology to measure onset of action. J Clin Psychiatry. 2001;62(Suppl 15):18–21. PubMed

Thompson C. Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol Clin Exp. 2002;17:S27–S32. PubMed

Zedkova I, Dudova I, Urbanek T, Hrdlicka M. Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses. Neuroendocrinol Lett. 2011;32:667–670. PubMed

Martinez-Ortega JM, Funes-Gogoy S, Diaz-Atienza F, Gutierrez-Rojas L, Perez-Costillas L, Gurpegui M. Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry. 2013;22:457–479. PubMed

Fleischhaker C, Heiser P, Hennighausen K, et al. Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm. 2007;114:273–280. PubMed

Hrdlicka M, Zedkova I, Blatny M, Urbanek T. Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: a retrospective study. Neuroendocrinol Lett. 2009;30:256–261. PubMed

Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765–1773. PubMed PMC

Arango C, Giraldez M, Merchan-Naranjo J, et al. Second-generation antipsychotic use in children and adolescents: a six-month prospective, cohort study in drug-naive patients. J Am Acad Child Adolesc Psychiatry. 2014;53:1179–1190. PubMed

Leucht S, Komossa A, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152–163. PubMed

Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:1837–1847. PubMed

Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163:2080–2089. PubMed

Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the Mozart study. Schizophr Res. 2009;110:80–89. PubMed

Blumer D. Catatonia and the neuroleptics: psychobiologic significance of remote and recent findings. Compr Psychiatry. 1997;38:193–201. PubMed

Sienaert P, Dhossche DM, Vancampfort D, De Hert M, Gazdag G. A clinical review of the treatment of catatonia. Front Psychiatry. 2014;5:181. PubMed PMC

DelBello MP, Foster KD, Strakowski SM. Case report: treatment of catatonia in an adolescent male. J Adolesc Health. 2000;27:69–71. PubMed

Dudova I, Hrdlicka M. Successful use of olanzapine in adolescent monozygotic twins with catatonic schizophrenia resistant to electro-convulsive therapy. Neuroendocrinol Lett. 2008;29:47–50. PubMed

Strawn JR, Delgado SV. Successful treatment of catatonia with aripiprazole in an adolescent with psychosis. J Child Adolesc Psychopharmacol. 2007;17:733–735. PubMed

Kirino E. Prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: a case report. Clin Schizophr Relat Psychoses. 2010;4:185–188. PubMed

Paraga H, Harris K. Catatonia under treatment with risperidone. J Dev Behav Pediatr. 2006;27:369. PubMed

Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1688–1696. PubMed

Webb S. Drugmakers dance with autism. Nat Biotechnol. 2010;28:772–774. PubMed